<p>美国银行证券的分析师 Travis Steed 重申了对 Inspire Medical Systems 的持有评级，并将目标价格维持在 53.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Travis Steed 给予持有评级的原因是多种因素的结合，主要围绕着在 AMA 最近的编码决定后，报销的不确定性。AMA 拒绝为 Inspire 的单导联舌下神经刺激系统引入新的 I 类 CPT 代码，而是决定修订现有代码，以明确在 2027 年初将 HGNS 排除在外，从而使近期和中期的编码可见性受到限制。</p>
<p>Travis 还指出，尽管 Inspire 可以修订并重新提交其在 9 月份 CPT 会议上的提案，但如果未能获得批准，将会将任何新代码及相关的报销变更推迟到 2029 年，延长不确定性期。考虑到未来的 RUC 流程可能会提高或降低医生费用，并且股票已经反映出在 53 美元目标价下的某种恢复潜力，他认为风险/回报是平衡的，因此维持中性（持有）立场。</p>

启迪医疗

<p>美国银行证券的分析师 Travis Steed 重申了对启迪医疗的持有评级，维持目标价为 53 美元。该决定受到美国医学会最近的编码决定影响，导致报销的不确定性，限制了近期到中期的可见性。新编码和报销变更的潜在延迟可能将不确定性延续至 2029 年，这使得 Steed 认为风险与回报是平衡的</p>

<p>Analyst Travis Steed from Bank of America Securities reiterated a Hold rating on Inspire Medical Systems and keeping the price target at $53.00.</p>
<div class="lb-trans"><p>美国银行证券的分析师 Travis Steed 重申了对 Inspire Medical Systems 的持有评级，并将目标价格维持在 53.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Travis Steed has given his Hold rating due to a combination of factors, primarily revolving around reimbursement uncertainty following the AMA’s recent coding decision. The AMA declined to introduce a new Category I CPT code for Inspire’s single-lead hypoglossal nerve stimulation system and instead moved to revise existing codes to explicitly carve out HGNS starting in early 2027, leaving near- to medium-term coding visibility limited.</p>
<div class="lb-trans"><p>Travis Steed 给予持有评级的原因是多种因素的结合，主要围绕着在 AMA 最近的编码决定后，报销的不确定性。AMA 拒绝为 Inspire 的单导联舌下神经刺激系统引入新的 I 类 CPT 代码，而是决定修订现有代码，以明确在 2027 年初将 HGNS 排除在外，从而使近期和中期的编码可见性受到限制。</p>
</div><p>Travis also notes that while Inspire can revise and resubmit its proposal for the September CPT meeting, missing approval there would delay any new code and related reimbursement changes to 2029, extending the period of uncertainty. Given that a future RUC process could either enhance or potentially reduce physician fees, and with shares already reflecting some recovery potential at a $53 price target, he views the risk/reward as balanced and therefore maintains a Neutral (Hold) stance.</p>
<div class="lb-trans"><p>Travis 还指出，尽管 Inspire 可以修订并重新提交其在 9 月份 CPT 会议上的提案，但如果未能获得批准，将会将任何新代码及相关的报销变更推迟到 2029 年，延长不确定性期。考虑到未来的 RUC 流程可能会提高或降低医生费用，并且股票已经反映出在 53 美元目标价下的某种恢复潜力，他认为风险/回报是平衡的，因此维持中性（持有）立场。</p>
</div>

Analyst Maintains Hold on Inspire as Reimbursement Uncertainty Persists; $53 Price Target Reaffirmed

Tip Ranks

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

分析师维持对启迪医疗的持有评级，因为报销的不确定性依然存在；重申 53 美元的目标价